Vanguard Information Technology Index Fund ETF vs DENTSPLY SIRONA Inc — how do they compare? Vanguard Information Technology Index Fund ETF trades at $127.54 (market cap $170.20B), while DENTSPLY SIRONA Inc trades at $8.82 (market cap $1.73B). The key difference: Vanguard Information Technology Index Fund ETF is far larger — about 98.4× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Vanguard Information Technology Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Information Technology Index Fund ETF for 129 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| VGT | XRAY | |
|---|---|---|
Market Cap | $170.20B | $1.73B |
Volume | 5,132,883 | 6,198,582 |
52-Week High | $129.79 | $14.68 |
52-Week Low | $83.59 | $8.52 |
Typical Hold Time | 129 Days | 72 Days |
Sector | — | Health |
Enterprise Value | — | $3.80B |
Dividend Yield | — | 5.04% |
Signals from Pluang's Aura AI — not financial advice
VGT trades at $127.00, down 1.83% today but maintains a bullish technical outlook with strong moving average support. The ETF's focus on pure-play technology stocks like Nvidia, Apple, and Microsoft has delivered exceptional historical returns, averaging over 17% annually for two decades according to The Motley Fool (2026-10-03). Recent institutional buying activity signals continued confidence in the tech sector's growth prospects.
While VGT offers concentrated tech exposure with low fees, investors face sector concentration risk and potential AI slowdown concerns. The ETF's exclusion of major tech names like Google and Amazon due to classification rules creates unexpected portfolio gaps. Current technical strength supports near-term upside, but macroeconomic headwinds could pressure tech valuations.
DENTSPLY SIRONA (XRAY) trades at $8.54, near its 52-week low, with bearish technical indicators and mixed fundamentals. The company reported Q2 2026 EPS of $0.52 beating expectations but revenue declined 4.1% year-over-year. Net income remains negative at -$598 million for 2025, though margins show slight improvement. Analyst consensus is mixed with 37.5% buy ratings but a $13.40 price target suggesting 57% upside potential from current levels.
The stock presents a high-risk turnaround opportunity with significant upside if management's restructuring efforts succeed, but faces headwinds from declining sales, margin pressure, and competitive challenges in dental markets. Institutional ownership changes and ongoing transformation investments create both uncertainty and potential for recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →